Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C4H5NO3S |
Molecular Weight | 147.152 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@@H]1CSC(=O)N1
InChI
InChIKey=BMLMGCPTLHPWPY-REOHCLBHSA-N
InChI=1S/C4H5NO3S/c6-3(7)2-1-9-4(8)5-2/h2H,1H2,(H,5,8)(H,6,7)/t2-/m0/s1
Molecular Formula | C4H5NO3S |
Molecular Weight | 147.152 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/9604807
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9604807
Oxothiazolidinecarboxylic Acid (L-2-oxothiazolidine-4-carboxylic acid, OTC) was currently undergoing evaluation in a Phase II clinical trial. It is suggested that an ideal drug may be an antisense oligonucleotide that blocks the expression of glycolate oxidase, a key enzyme in hepatic oxalate synthesis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10227642
Curator's Comment: Procysteine enters CSF after both IV and oral dosing and accumulates to significant levels in CSF. It was also observed that CSF levels of glutathione fall dramatically with aging.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL247 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9144376 |
|||
Target ID: P48637 Gene ID: 2937.0 Gene Symbol: GSS Target Organism: Homo sapiens (Human) Sources: http://adisinsight.springer.com/drugs/800002203 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
734 nmol/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9590463 |
4500 mg single, oral dose: 4500 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXOTHIAZOLIDINECARBOXYLIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
242 nmol/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9590463 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXOTHIAZOLIDINECARBOXYLIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
105 nmol/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9590463 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXOTHIAZOLIDINECARBOXYLIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4063 nmol × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9590463 |
4500 mg single, oral dose: 4500 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXOTHIAZOLIDINECARBOXYLIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
428 nmol × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9590463 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXOTHIAZOLIDINECARBOXYLIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
88 nmol × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9590463 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXOTHIAZOLIDINECARBOXYLIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg/kg 1 times / 8 hours multiple, intravenous Highest studied dose Dose: 100 mg/kg, 1 times / 8 hours Route: intravenous Route: multiple Dose: 100 mg/kg, 1 times / 8 hours Sources: Page: p.35 |
healthy, ADULT n = 6 Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Population Size: 6 Sources: Page: p.35 |
|
0.5 g 3 times / day multiple, oral Studied dose Dose: 0.5 g, 3 times / day Route: oral Route: multiple Dose: 0.5 g, 3 times / day Sources: Page: p.1097 |
unhealthy, ADULT n = 10 Health Status: unhealthy Condition: renal failure - chronic Age Group: ADULT Sex: M+F Food Status: FED Population Size: 10 Sources: Page: p.1097 |
PubMed
Title | Date | PubMed |
---|---|---|
L-2-oxothiazolidine-4-carboxylic acid, a cysteine prodrug: pharmacokinetics and effects on thiols in plasma and lymphocytes in human. | 1991 Apr |
|
The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosis. | 1999 Apr 22 |
|
Dietary antioxidants prevent alcohol-induced ciliary dysfunction. | 2013 Dec |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2019996
Oxothiazolidinecarboxylic Acid (L-2-oxothiazolidine-4-carboxylic acid, OTC), a prodrug of cysteine, was administered at a dose of 0.15 and 0.45 mmol/kg to healthy volunteers. The plasma concentration of OTC reached a peak between 45 and 60 min after p.o. administration.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9144376
Oxothiazolidinecarboxylic Acid (L-2-oxothiazolidine-4-carboxylic acid, OTC) was tested at concentrations of 5, 10, and 20 mM for its effect on acute
and chronic HIV-1 infection as measured by RT activity in
MDM isolated from adult peripheral blood and cord blood. Addition of OTC at a concentration
of 10 or 20 mM to chronically infected cord blood
MDM cultures also suppressed RT activity during the subsequent
course of infection.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:52:42 GMT 2023
by
admin
on
Sat Dec 16 01:52:42 GMT 2023
|
Record UNII |
X7063P804E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
99296
Created by
admin on Sat Dec 16 01:52:42 GMT 2023 , Edited by admin on Sat Dec 16 01:52:42 GMT 2023
|
||
|
FDA ORPHAN DRUG |
81994
Created by
admin on Sat Dec 16 01:52:42 GMT 2023 , Edited by admin on Sat Dec 16 01:52:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m8319
Created by
admin on Sat Dec 16 01:52:42 GMT 2023 , Edited by admin on Sat Dec 16 01:52:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
X7063P804E
Created by
admin on Sat Dec 16 01:52:42 GMT 2023 , Edited by admin on Sat Dec 16 01:52:42 GMT 2023
|
PRIMARY | |||
|
19771-63-2
Created by
admin on Sat Dec 16 01:52:42 GMT 2023 , Edited by admin on Sat Dec 16 01:52:42 GMT 2023
|
PRIMARY | |||
|
X7063P804E
Created by
admin on Sat Dec 16 01:52:42 GMT 2023 , Edited by admin on Sat Dec 16 01:52:42 GMT 2023
|
PRIMARY | |||
|
1926836
Created by
admin on Sat Dec 16 01:52:42 GMT 2023 , Edited by admin on Sat Dec 16 01:52:42 GMT 2023
|
PRIMARY | |||
|
72390
Created by
admin on Sat Dec 16 01:52:42 GMT 2023 , Edited by admin on Sat Dec 16 01:52:42 GMT 2023
|
PRIMARY | |||
|
DB12224
Created by
admin on Sat Dec 16 01:52:42 GMT 2023 , Edited by admin on Sat Dec 16 01:52:42 GMT 2023
|
PRIMARY |